Bionano Genomics Inc

Important metrics include cash and short-term investments, total assets, current assets, total liabilities, current liabilities, long-term debt, shareholders' equity, retained earnings, inventory, receivables, working capital, current ratio, quick ratio, debt-to-equity ratio, and return on equity. Investors usually review these together rather than relying on one number.

Assets are resources the company owns or controls, such as cash, receivables, inventory, investments, and property. Liabilities are obligations the company owes, such as accounts payable, debt, leases, and taxes. Shareholders' equity is the residual value after liabilities are subtracted from assets.

Current assets and current liabilities are generally expected to be converted, used, paid, or settled within one year or one operating cycle. Non-current assets and non-current liabilities are longer-term items, such as property, long-term investments, deferred tax assets, long-term debt, and lease obligations.

In its most recent quarterly, Bionano Genomics Inc had 3.42M in cash and cash equivalents.

Bionano Genomics Inc reported 29.16M in total liabilities as of the latest reported quarter, including 22.94M in current liabilities and 6.22M in non-current liabilities.

As of the latest reported quarter, Bionano Genomics Inc's total assets were 73.58M, consisting of 45.39M in current assets and 28.20M in non-current assets.

Bionano Genomics Inc reported 44.42M in total shareholders' equity as of the latest reported quarter.